Cite
Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months.
MLA
Haworth, Charles S., et al. “Inhaled Colistimethate Sodium in Patients with Bronchiectasis and Pseudomonas Aeruginosa Infection: Results of PROMIS-I and PROMIS-II, Two Randomised, Double-Blind, Placebo-Controlled Phase 3 Trials Assessing Safety and Efficacy over 12 Months.” Lancet Respiratory Medicine, vol. 12, no. 10, Oct. 2024, pp. 787–98. EBSCOhost, https://doi.org/10.1016/S2213-2600(24)00225-X.
APA
Haworth, C. S., Shteinberg, M., Winthrop, K., Barker, A., Blasi, F., Dimakou, K., Morgan, L. C., O’Donnell, A. E., Ringshausen, F. C., Sibila, O., Thomson, R. M., Carroll, K. J., Pontenani, F., Castellani, P., & Chalmers, J. D. (2024). Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months. Lancet Respiratory Medicine, 12(10), 787–798. https://doi.org/10.1016/S2213-2600(24)00225-X
Chicago
Haworth, Charles S, Michal Shteinberg, Kevin Winthrop, Alan Barker, Francesco Blasi, Katerina Dimakou, Lucy C Morgan, et al. 2024. “Inhaled Colistimethate Sodium in Patients with Bronchiectasis and Pseudomonas Aeruginosa Infection: Results of PROMIS-I and PROMIS-II, Two Randomised, Double-Blind, Placebo-Controlled Phase 3 Trials Assessing Safety and Efficacy over 12 Months.” Lancet Respiratory Medicine 12 (10): 787–98. doi:10.1016/S2213-2600(24)00225-X.